A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007
Enrolling by invitation
Conditions studied: T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoblastic Lymphoma
In brief
This study will provide long-term follow-up for patients who have received treatment with WU-CART-007 in a previous clinical trial. In this study, patients will be followed for up to 15 years after their last dose of WU-CART-007 for evaluation of delayed adverse events, presence of persisting WU-CART-007 vector sequences, and overall survival and progression-free survival.
Key facts
- Study ID
- NCT05509855
- Run by
- Allotera Therapeutics
- People needed
- 44
- Starts
- 2022-08-22
- Expected to finish
- 2037-07-01
- Last updated by the study team
- 2024-11-20
Who can join
Age: 12 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- City of Hope — Duarte, California, United States
- Childrens Hospital LA — Los Angeles, California, United States
- Washington University — St Louis, Missouri, United States
- Children's Hospital of Philadelphia — Philadelphia, Pennsylvania, United States
- Peter MacCullam Cancer Center — Melbourne, Australia
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.